Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.
The Office of Health Economics (OHE) launched a biennial competition in early 2022 to answer the question ‘How can policymakers design a system to generate fair prices that balances access and innovation throughout the lifecycle of medicines?’ Join the live online ceremony on 24 January 2023.
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
